
Louis S Matza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/657675/publications.pdf Version: 2024-02-01



Ι ΟΙΙΙς S ΜΑΤΖΑ

#	Article	IF	CITATIONS
1	Health state utilities associated with weight loss in type 2 diabetes and obesity. Journal of Medical Economics, 2022, 25, 14-25.	2.1	3
2	Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma. PharmacoEconomics - Open, 2022, 6, 367-376.	1.8	6
3	Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes. Patient, 2022, 15, 367-377.	2.7	7
4	Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research, 2021, 30, 2033-2043.	3.1	7
5	Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 367.e7-367.e17.	1.6	4
6	Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. Value in Health, 2021, 24, 812-821.	0.3	39
7	Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments. Diabetes Therapy, 2021, 12, 2387-2403.	2.5	10
8	A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities. Diabetes Therapy, 2021, 12, 2827-2856.	2.5	6
9	Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism, 2020, 22, 355-364.	4.4	31
10	Health state utilities associated with treatment for transfusion-dependent Î ² -thalassemia. European Journal of Health Economics, 2020, 21, 397-407.	2.8	9
11	Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy. Diabetes Therapy, 2020, 11, 319-330.	2.5	4
12	A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. Medical Decision Making, 2020, 40, 897-911.	2.4	5
13	<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p> . Patient Preference and Adherence, 2020, Volume 14, 2231-2242.	1.8	8
14	Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS). Journal of Medical Economics, 2020, 23, 978-984.	2.1	4
15	Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV. Patient, 2020, 13, 409-422.	2.7	6
16	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0
17	Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ). Journal of Patient-Reported Outcomes, 2020, 4, 104.	1.9	0
18	Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS). Multiple Sclerosis and Related Disorders, 2019, 35, 253-261.	2.0	4

LOUIS S MATZA

#	Article	IF	CITATIONS
19	Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). Journal of Medical Economics, 2019, 22, 936-944.	2.1	7
20	Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. Drugs in R and D, 2019, 19, 213-225.	2.2	10
21	Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. Journal of Medical Economics, 2019, 22, 806-813.	2.1	18
22	Health state utilities associated with post-surgical Staphylococcus aureus infections. European Journal of Health Economics, 2019, 20, 819-827.	2.8	15
23	Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Quality of Life Research, 2019, 28, 2359-2372.	3.1	15
24	Health state utilities associated with treatment options for acute myeloid leukemia (AML). Journal of Medical Economics, 2019, 22, 567-576.	2.1	6
25	Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews. Multiple Sclerosis and Related Disorders, 2019, 27, 139-146.	2.0	15
26	Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Current Medical Research and Opinion, 2018, 34, 1457-1464.	1.9	22
27	Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). Journal of Patient-Reported Outcomes, 2018, 2, 44.	1.9	8
28	Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). Journal of Patient-Reported Outcomes, 2018, 2, 43.	1.9	10
29	Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. Patient Preference and Adherence, 2018, Volume 12, 971-979.	1.8	13
30	Challenges of Developing an Observable Parent-Reported Measure: A Qualitative Study of Functional Impact of ADHD in Children. Value in Health, 2017, 20, 828-833.	0.3	6
31	Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation. Quality of Life Research, 2017, 26, 1785-1798.	3.1	7
32	Health State Utilities Associated with Glucose Monitoring Devices. Value in Health, 2017, 20, 507-511.	0.3	28
33	Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Services Research, 2017, 17, 774.	2.2	23
34	Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence, 2016, Volume 10, 1385-1399.	1.8	56
35	Physician perceptions of GLP-1 receptor agonists in the UK. Current Medical Research and Opinion, 2016, 32, 857-864.	1.9	20
36	The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. European Journal of Health Economics, 2016, 17, 979-990.	2.8	17

LOUIS S MATZA

#	Article	IF	CITATIONS
37	A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. Health and Quality of Life Outcomes, 2015, 13, 192.	2.4	20
38	Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Services Research, 2015, 15, 173.	2.2	47
39	Health state utilities associated with attributes of treatments for hepatitis C. European Journal of Health Economics, 2015, 16, 1005-1018.	2.8	35
40	Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2). Patient, 2015, 8, 433-443.	2.7	8
41	Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes, 2015, 13, 90.	2.4	27
42	Health state utilities associated with adult attention-deficit/hyperactivity disorder. Patient Preference and Adherence, 2014, 8, 997.	1.8	7
43	Health state utilities for skeletal-related events secondary to bone metastases. European Journal of Health Economics, 2014, 15, 7-18.	2.8	21
44	Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions. Health and Quality of Life Outcomes, 2014, 12, 48.	2.4	18
45	The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition. Quality of Life Research, 2013, 22, 351-360.	3.1	12
46	A systematic literature review of cardiovascular event utilities. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 767-790.	1.4	14
47	Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force. Value in Health, 2013, 16, 461-479.	0.3	322
48	Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Preference and Adherence, 2013, 7, 855.	1.8	23
49	Development and validation of a patient-report measure of fatigue associated with depression. Journal of Affective Disorders, 2011, 134, 294-303.	4.1	19
50	Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. European Journal of Health Economics, 2011, 12, 219-230.	2.8	103
51	Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Current Medical Research and Opinion, 2007, 23, 2051-2062.	1.9	21
52	Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. Health and Quality of Life Outcomes, 2007, 5, 47.	2.4	56
53	Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality of Life Research, 2007, 16, 1251-1265.	3.1	102
54	Health State Utilities for Childhood Attention-Deficit/Hyperactivity Disorder Based on Parent Preferences in the United Kingdom. Medical Decision Making, 2005, 25, 56-70.	2.4	52

#	Article	IF	CITATIONS
55	The Link Between Health-Related Quality of Life and Clinical Symptoms Among Children with Attention-Deficit Hyperactivity Disorder. Journal of Developmental and Behavioral Pediatrics, 2004, 25, 166-174.	1.1	104